August 4, 2020
Strongbridge Biopharma plc Reports Second Quarter 2020 Financial Results and Provides Corporate Update
~ Reports KEVEYIS® (dichlorphenamide) Second Quarter 2020 Revenue of $7.8 Million, a 28 Percent Increase Compared to $6.1 Million During Second Quarter of 2019 ~
~ Co...
Read more
Read more
August 4, 2020
GenSight Biologics draws down the €4 million second tranche of bonds from Kreos Capital
Paris, France, August 4, 2020, 7.30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the “Company” or “GenSight“), a biopharma compa...
Read more
Read more
July 30, 2020
Nordic Nanovector Announces EU Patent Granted Covering the Use of Alpha37
Oslo, Norway, 30 July 2020
Nordic Nanovector ASA (OSE: NANO) is pleased to announce the grant of an EU patent covering the use of Alpha37 for the treatment of Chronic ...
Read more
Read more
July 30, 2020
GenSight Biologics Reports Interim Financial Results for the First Half of 2020 and Provides Operational Update
Paris, France, July 30, 2020, 7.30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and...
Read more
Read more
July 28, 2020
Strongbridge Biopharma plc to Host Second Quarter 2020 Financial Results Conference Call on August 4, 2020
DUBLIN, Ireland and TREVOSE, Pa., July 28, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on ...
Read more
Read more
July 27, 2020
Vicore Pharma doses first COVID-19 patient in the ATTRACT study in India
Gothenburg, July 27, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces th...
Read more
Read more
July 27, 2020
CARISMA Therapeutics Announces FDA Clearance of IND Application for First-Ever Engineered Macrophage Immunotherapy
PHILADELPHIA, July 27, 2020 /PRNewswire/ -- CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announ...
Read more
Read more
July 22, 2020
GenSight Biologics reports final REALITY natural history study results confirming poor spontaneous recovery for LHON patients with ND4 mutation
Paris, France, Tuesday, July 21, 2020, 7.30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and ...
Read more
Read more
July 17, 2020
Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
Commenced expansion cohort in combination with venetoclax and azacitidine
Added cohort to be activated in combination with azacitidine
BOSTON, July 16, 2020 (GLOBE NEWS...
Read more
Read more
July 17, 2020
Orexo Interim Report Q2 2020
Investing in diversification to drive future growth
Q2 2020 highlights
Total net revenues of SEK 179.1 m (201.2)
EBITDA of SEK -9.0 m (60.4), positive EBITDA of SEK 26.5...
Read more
Read more